AbbVie Inc.(ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Latest News & Analysis
AbbVie's EPKINLY Approval Validates Oncology Platform as Third Pillar of Transformation
EPKINLY FDA approval validates AbbVie's oncology platform as transformation pillar, extending growth beyond immunology dependency.
AbbVie's Q3 Earnings Prove Transformation Thesis—But Humira Cliff Threatens Momentum
Q3 beat and raised guidance validate Rinvoq and Skyrizi momentum; market's post-earnings pullback signals skepticism over Humira decline acceleration risk.
Rinvoq's Vitiligo Victory Validates AbbVie's Multi-Indication Franchise Strategy
Phase 3 vitiligo success validates Rinvoq's multi-indication platform, proving AbbVie can capture greenfield markets with zero systemic competitors.
Rinvoq's Clinical Triumph Over Humira Validates AbbVie's Immunology Transformation
Rinvoq beats Humira in head-to-head trial; bretisilocin acquisition and Strong Buy upgrade validate AbbVie's post-Humira transformation strategy.
AbbVie's 2025 Outlook: Strategic Pipeline Expansion Amidst Market Shifts
A data-driven review of AbbVie’s 2025 strategic shift, leadership transition, pipeline expansion, and market dynamics.
AbbVie's Growth Strategy: Skyrizi & Rinvoq Offset Humira Decline
Explore AbbVie's strategic evolution as robust immunology growth offsets Humira's decline and drives future innovation.
AbbVie's Post-Humira Strategy: Growth, Dividends & Outlook
Intraday update on AbbVie Inc.'s strategic shifts beyond Humira with strong dividends, growth drivers, and key acquisitions.
AbbVie's Growth Strategy Beyond Humira: Diversification, Dividends, and New Drug Pipeline
AbbVie navigates Humira biosimilar impact with strategic diversification, robust pipeline, and commitment to dividends. Skyrizi and Rinvoq drive future growth.
AbbVie's Post-Humira Strategy: Pipeline Growth and Market Impact
AbbVie faces Humira biosimilar challenges, but Skyrizi and Rinvoq drive growth. Leadership transition and strategic acquisitions shape future outlook. All data from Monexa AI.
AbbVie's Growth Strategy Beyond Humira: Skyrizi, Rinvoq, and Future Prospects
AbbVie is driving growth with Skyrizi, Rinvoq, and strategic acquisitions while transitioning beyond Humira to secure long-term value.
AbbVie's Strategic Shift: Navigating Humira's Decline
AbbVie navigates Humira's decline with Skyrizi, Rinvoq growth, strategic collaborations, and a focus on shareholder value, positioning it for future success.
AbbVie (ABBV): Navigating the Pharmaceutical Landscape in 2025
AbbVie navigates Humira biosimilar competition, focusing on its immunology and oncology pipelines, strategic collaborations, and dividend growth.
AbbVie: Navigating Market Shifts and Pipeline Expansion in 2025
AbbVie navigates Humira biosimilar impact, driving growth through Skyrizi and Rinvoq. Analysis of Q4 2024 results, strategies, and outlook.
AbbVie (ABBV) Analysis: RINVOQ, Dividends, and Future Growth [2025]
AbbVie (ABBV) navigates biosimilar competition with RINVOQ's potential and a strong dividend, shaping its future growth. Strategic shifts impact investors.
AbbVie Inc. Intraday Update: Strategic Moves in the Obesity Market
Data-driven update on AbbVie Inc. intraday activity, highlighting a $2.2B Gubra deal, strategic pipeline moves, and robust dividend signals.
AbbVie's Strategic Shift: Obesity Market Entry & European Expansion
AbbVie targets obesity market, expands RINVOQ in Europe, and navigates inflation. A strategic analysis for investors.
AbbVie (ABBV) Enters Weight Loss Market: A Financial Analysis
AbbVie (ABBV) is strategically entering the weight loss market with GUB014295 amidst Humira biosimilar challenges. This analysis covers the science, competition, financial impact, and analyst outlook.
AbbVie's Obesity Bet: GUBamy, Market Competition, and Legal Risks (ABBV)
AbbVie strategically enters the obesity market with GUBamy, facing Humira biosimilar competition and legal challenges, while leveraging its dividend yield for stability.
AbbVie (ABBV) Stock Analysis: Navigating Obesity, ELAHERE, Dividends
AbbVie (ABBV) navigates the obesity market with GUBamy, showcases ELAHERE's impact in ovarian cancer, and maintains dividend resilience amidst Humira biosimilar challenges.
AbbVie's Strategic Shift: Weight Loss, Oncology, and Dividend Focus
AbbVie navigates Humira biosimilar impact with strategic moves in weight loss (GUBamy), oncology (ELAHERE), and sustained dividend growth amidst debt concerns.
AbbVie: Oncology Pipeline, Weight Loss Strategy, and Dividend Outlook
AbbVie (ABBV) expands its portfolio with oncology advancements, a strategic entry into weight loss, and a steadfast commitment to dividend sustainability.
AbbVie (ABBV): Acquisition Expenses, Humira Challenges, and Dividend Strength
AbbVie (ABBV) navigates acquisition expenses and Humira biosimilar competition, focusing on Skyrizi and Rinvoq growth. Dividend strength and defensive stock appeal in market uncertainty.
AbbVie (ABBV): Rinvoq's EU Approval, Dividend Yield and Challenges
AbbVie (ABBV) faces headwinds from acquisition costs and Humira biosimilar competition, but Rinvoq's EU approval and a solid dividend yield offer some stability. A deep dive.
AbbVie Inc. (ABBV): Post-Humira Strategy and Pipeline Strength
Explore AbbVie's strategic shifts, financial health, and pipeline strength, anchored by recent ASCO data and earnings performance.
AbbVie's Strategic Approvals: MAVYRET and RINVOQ Reshape Revenue
AbbVie's recent FDA approvals for MAVYRET and RINVOQ are set to significantly boost revenue, reshape treatment standards, and mitigate patent cliff risks.
AbbVie (ABBV): Pipeline Successes & Financial Resilience in 2025
AbbVie Inc. navigates post-Humira era with key FDA approvals for RINVOQ and MAVYRET, driving future revenue growth despite margin pressures.
AbbVie (ABBV): Navigating Clinical Setbacks with Strategic Resilience
AbbVie's stock dipped after a clinical trial setback, but its diversified pipeline and strategic investments offer resilience and future growth.
AbbVie's Dual FDA Approvals: MAVYRET & Emrelis Drive Strategic Growth
AbbVie secures pivotal FDA approvals for MAVYRET® in hepatitis C and Emrelis in lung cancer, signaling strategic portfolio diversification and potential for significant revenue growth.
AbbVie Inc. (ABBV): Financial & Pipeline Developments in 2025
AbbVie navigates financial shifts with recent dividend declaration, strategic acquisitions, and critical pipeline advancements, shaping its market position.
AbbVie's Strategic Shifts: Clinical Wins, Financial Resilience
AbbVie's strategic pivot gains momentum with strong clinical wins and significant M&A, reshaping its financial future post-Humira.
AbbVie (ABBV) Analysis: Pipeline Fuels Growth Amidst Market Shifts
AbbVie's strategic pivot towards specialized oncology and immunology assets, driven by key approvals, is reshaping its future amidst market shifts.
AbbVie (ABBV): Skyrizi & Rinvoq Drive Post-Humira Growth Surge
AbbVie's post-Humira strategy thrives as Skyrizi and Rinvoq drive revenue surge, offsetting biosimilar impact. Learn how oncology and pipeline advancements secure its future.
AbbVie Inc. Strategic Leap with $2.1B Capstan Acquisition and Financial Insights - Monexa AI
AbbVie’s $2.1B acquisition of Capstan Therapeutics marks a strategic pivot to in vivo CAR-T therapies, reshaping its immunology pipeline amid Humira revenue shifts.
AbbVie Inc. Advances Immunology Pipeline with $2.1B Capstan Acquisition | Market & Financial Analysis
AbbVie’s $2.1B Capstan acquisition pioneers in vivo CAR-T for autoimmune diseases, reshaping its immunology pipeline and financial outlook.
AbbVie Inc. Strategic $2.1B Capstan Acquisition Enhances Immunology Pipeline and Post-Humira Growth
AbbVie's $2.1B acquisition of Capstan Therapeutics boosts its immunology pipeline with innovative in vivo CAR-T tech, addressing post-Humira growth and market positioning.
AbbVie Inc. Growth Strategy and Financial Performance Update - Monexa AI
AbbVie drives growth post-Humira with Skyrizi, Rinvoq, and oncology innovations, supported by strong financials and strategic diversification.
AbbVie Inc. (ABBV) Market Analysis: Oncology Growth and Financial Dynamics
AbbVie advances oncology and immunology strategies amid biosimilar pressures, leveraging pipeline innovation and robust cash flow to sustain growth.
AbbVie Inc. Strategic Pipeline Expansion and Financial Overview Amidst Post-Humira Transition
AbbVie's aggressive pipeline expansion in oncology and immunology, including ISB 2001 and Capstan Therapeutics acquisition, underpins its growth beyond Humira.
AbbVie Inc. (ABBV) Latest Developments & Financial Insights - Strategic Market Analysis
Explore AbbVie Inc.'s recent market movements, financial performance, and strategic initiatives impacting its fundamentals and investor outlook.
AbbVie Inc. Market Update: Immunology Growth, Oncology Expansion & Strategic M&A Boost 2025 Prospects
AbbVie accelerates post-Humira growth with Skyrizi and Rinvoq, bolstered by oncology pipeline and strategic M&A, driving 2025 revenue and EPS outlook.
AbbVie (ABBV) Analysis: Emrelis Approval, Growth Drivers, and Dividend Sustainability
AbbVie's strategic moves, including the Emrelis FDA approval and strong Skyrizi/Rinvoq performance, are navigating post-Humira dynamics. Dive into the financials.
AbbVie Inc. Q2 2025 Earnings Analysis: Immunology Growth Amid Humira Decline - Monexa AI
AbbVie Q2 2025 earnings reveal strong Skyrizi and Rinvoq growth offsetting Humira's decline, with strategic acquisitions shaping future biopharma positioning.
AbbVie Inc. Q2 2025 Earnings: Immunology Growth and Strategic Acquisitions Drive Future Outlook
AbbVie's Q2 2025 earnings beat expectations with strong immunology sales and Capstan acquisition, navigating biosimilar pressures and regulatory challenges.
AbbVie Inc. (ABBV) Latest Corporate Developments and Financial Insights
Explore AbbVie's recent financial performance, strategic moves, and market positioning with data-backed insights on revenue, earnings, and dividend sustainability.
AbbVie Inc.: $195M U.S. API Build, Debt & Dividend Dynamics
Deep dive on AbbVie's $195M North Chicago API investment, 2024 financials, rising net debt, high payout ratio, and implications for operational resilience.
AbbVie Inc. Q2 2025 Analysis: Skyrizi & Rinvoq Drive Growth Amid Biosimilar Pressure
AbbVie Q2 2025 highlights strong immunology growth led by Skyrizi and Rinvoq, strategic Capstan acquisition, and sustained dividend backed by robust cash flow.
AbbVie Inc. (ABBV): Capital-Light Pivot to Next‑Gen Immunology Amid Rising Leverage
AbbVie’s $2.1B Capstan buy and FY2024 cash flow strength mask rising leverage and compressed profits — here’s what the numbers and strategy together imply.
AbbVie (ABBV): Cash-Heavy, Deal-Driven Year Leaves Dividend Intact — But Leverage and Intangibles Rise
AbbVie's FY2024 shows **$56.33B revenue**, **$17.83B free cash flow** and **$62.3B net debt** after **$17.5B** of acquisitions — dividend covered by FCF, but leverage and goodwill are material risks.
AbbVie Inc. (ABBV): M&A-Fueled Growth vs. Leverage Stress
AbbVie’s $1.2B Gilgamesh buy and Rinvoq momentum are backed by strong cash flow, but rising leverage and an elevated payout create strategic trade-offs for investors.
AbbVie Inc.: $1.2B Psychedelic Bet and Rinvoq’s Alopecia Breakthrough — What the Numbers Reveal
AbbVie’s $1.2B bretisilocin acquisition and Rinvoq Phase‑3 success arrive alongside a Q2 beat and upgraded guidance; cash flow strength masks rising leverage and near‑term EPS headwinds.
AbbVie Inc. (ABBV): Diversification, Cash Flow and a Stretched Balance Sheet
AbbVie beat Q2 estimates with adjusted EPS of **$2.97** (+3.13%) and raised guidance, but heavy M&A and elevated goodwill have pushed net debt to **$62.3B** and compressed GAAP margins.
AbbVie Inc. (ABBV): Earnings, Cash Flow and Leverage Review
AbbVie’s FY2024 shows resilient cash flow but compressed earnings and higher leverage after large M&A; forward EPS growth reshapes dividend coverage and valuation.
AbbVie (ABBV) — Post‑Humira Reinvestment, Cash Flow Strength, and Rising Leverage
AbbVie posted **FY2024 revenue of $56.33B** while investing heavily in R&D and acquisitions; free cash flow stayed high at **$17.83B** even as net income and equity compressed.
AbbVie's Post-Humira Pivot Gains Momentum as Pipeline Milestones Drive Stock Surge
Clinical breakthroughs in neuroscience, manufacturing expansion, and bold UK pricing validate the pharmaceutical giant's diversification beyond immunology.